New drug with enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called CP-PCA07 combined with enzalutamide for men whose prostate cancer has stopped responding to enzalutamide or abiraterone. The goal is to see if the combination is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 19 or older.
- You have prostate cancer that keeps growing even when testosterone is very low (below 50 ng/dL).
- You have already tried either enzalutamide or abiraterone alone and it stopped working (your PSA went up).
- Your PSA has increased by at least 50% and is at least 2 ng/mL, confirmed by two tests.
- You are generally able to care for yourself (ECOG score 0 to 2) and expected to live at least 6 more months.
- You agree to use effective birth control if your partner could become pregnant, and you have not had recent chemotherapy, radiation, or major surgery that could interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Hear when a new Castration-Resistant Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.